On December 6, the 12th "Shulan Medical Award" award ceremony was held in Hangzhou. This year, a total of 3 winners of the "Shulan Medical Award" and 15 "Shulan Medical Youth Award" were selected. Among them, Shu Yilai, an alumnus of the Batch 1999 of Otolaryngology from Hengyang Medical College of our school, won the "Shulan Medical Youth Award".

It is reported that the Shulan Medical Award is an award established by the Shusen Lanjuan Academician Talent Fund Council of Zhejiang University Education Foundation, which is committed to the cultivation of Chinese medical talents, with the purpose of developing education, supporting new talents, and rewarding talents, focusing on rewarding outstanding scientific and technological talents of Chinese nationality (including Hong Kong, Macao and Taiwan) who have made breakthrough innovations in the field of medicine, and cultivating world-class medical scientists, so as to further promote the development of Chinese medical science.

After more than 10 years of development, the "Shulan Medical Award" has become a model of high-end talent awards in our country's medical and health fields with strict nominations, high-level review experts and authoritative selection records, and has a great influence in the field of medicine and health in China.

Shu Yilai, professor, chief physician. He graduated from the Major of Otolaryngology of the Department of Clinical Medicine of the University of South China in 2004 and completed his master's and doctoral studies at the Eye and Otolaryngology Hospital of Fudan University in 2012. He is currently the vice president of the Eye and Ear Laryngologist Hospital Affiliated to Fudan University, the director of the Shanghai Key Laboratory of Gene Editing and Cell Therapy for Rare Diseases, and the academic leader of the National Natural Innovation Research Group Project (the first in this field). Master the diagnosis and treatment of otolaryngology, head and neck surgical diseases, and specialize in ear surgery and three-level prevention and control of deafness. Focusing on the R&D and clinical transformation of deafness gene therapy, it has developed OTOF deafness gene therapy drugs and equipment, led the world's first clinical trial of gene therapy for congenital deafness, corrected the hearing, speech and sound source localization ability of deaf patients, and realized the etiology of deafness and a subversive paradigm change. He has published more than 60 SCI papers as a corresponding author and led the first international expert consensus on gene therapy for hereditary deafness. He has won the ARO Clinical Science Innovation Award (the first in Asia), the Shanghai Youth Science and Technology Outstanding Contribution Award, the Scientific Exploration Award, and the Shangsi Exploration Scholar.